Fox Advisors analyst Steven Fox earlier today initiated coverage of Versigent (VGNT) with an Outperform rating and $35 price target The firm views the shares as “mispriced” following the spinout by Aptiv.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VGNT: